News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioGaia Makes Further Investment In Metabogen



11/30/2016 8:57:08 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:

In December 2014 BioGaia reported its decision to invest SEK 12 million in MetaboGen AB, Gothenburg, Sweden. The investment should be made over a two-year period. The first investment of SEK 4 million took place in December 2014 and the second in December 2015 and as MetaboGen has reached the agreed milestones the last investment of SEK 4 million was made today.

BioGaia thereafter owns 36% of the share capital of MetaboGen.

MetaboGen is a research company, which was founded in 2011 in Gothenburg by Professor Fredrik Bäckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology together with GU Holding, which commercializes research results and develops companies linked to the University of Gothenburg. MetaboGen researches in metagenomics, the research intensive and fast developing field of gene sequencing of all genes in the microbial communities of for example the human gut, to find previously unknown members and patterns of the microbial diversity related to health and disease. The aim is to develop new treatments and products for different metabolic and other microbial associated diseases by influencing large parts of the microbiota.

Peter Rothschild is Chairman of the Board and Sara Malcus is President in MetaboGen AB. For further information please see BioGaia´s press release from 1 December 2014 and 2015 on BioGaia´s website: www.biogaia.com/pressreleases

BioGaia (STO:BIOGB) is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health- enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. biogaia.com (http://www.biogaia.com).

BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan 3, Stockholm Telephone: +46 8 555 293 00, Corp. identity no. 556380-8723. biogaia.com (http://www.biogaia.com).

This information was brought to you by Cision http://news.cision.com

Contacts

For additional information please contact
Peter Rothschild, Group President,
BioGaia: 46 8 555 293 00
or
Axel Sjöblad, Managing Director,
BioGaia: 46 8 555 293 00


Read at BioSpace.com


comments powered by Disqus
BioGaia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES